cyproheptadine has been researched along with fluorouracil in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (28.57) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 3 (42.86) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Ahlquist, DA; Dose, AM; Everson, LK; Kardinal, C; Loprinzi, CL; Miser, AW; Moertel, CG | 1 |
| Caspary, W; Rasenack, U | 1 |
| Dygai, AM; Ermakova, NN; Firsova, TV; Goldberg, ED; Minakova, MY; Pershina, OV; Skurikhin, EG | 1 |
| Andreeva, TV; Borsuk, OS; Dygaĭ, AM; Ermakova, NN; Khmelevskaia, ES; Pershina, OV; Skurikhin, EG | 1 |
| Abdalla, AM; Abdelbaky, FAF; Abdelzaher, WY; Hafez, SMNA; Khalaf, HM; Welson, NN | 1 |
1 review(s) available for cyproheptadine and fluorouracil
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for cyproheptadine and fluorouracil
| Article | Year |
|---|---|
Cancer control research in the North Central Cancer Treatment Group (NCCTG).
Topics: Allopurinol; Anorexia; Antineoplastic Agents; Cachexia; Clinical Trials as Topic; Colorectal Neoplasms; Cyproheptadine; Delayed-Action Preparations; Fluorouracil; Humans; Midwestern United States; Morphine; Mouthwashes; Neoplasms; Research; Stomatitis | 1989 |
5 other study(ies) available for cyproheptadine and fluorouracil
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
[Therapy of carcinoid and the carcinoid syndrome].
Topics: Aminocaproic Acid; Aprotinin; Carcinoma, Squamous Cell; Cyproheptadine; Doxorubicin; Embolization, Therapeutic; Fenclonine; Fluorouracil; Hepatic Artery; Humans; Intestinal Neoplasms; Liver Neoplasms; Malignant Carcinoid Syndrome; Methyldopa; Methysergide | 1983 |
Potentiation of the stimulatory effect of erythropoietin on erythropoiesis by antiserotonin drug during cytostatic myelosuppression.
Topics: Animals; Bone Marrow; Cyproheptadine; Erythropoiesis; Erythropoietin; Female; Fluorouracil; Immunosuppressive Agents; Mice; Mice, Inbred CBA; Serotonin Antagonists | 2009 |
[Erythropoiesis-stimulating properties of an antiserotonin drug under cytostatic treatment conditions].
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Agents, Alkylating; Bone Marrow; Cell Proliferation; Cyclophosphamide; Cyproheptadine; Erythroid Precursor Cells; Erythropoiesis; Fluorouracil; Male; Mice; Mice, Inbred CBA; Serotonin Antagonists | 2010 |
Role of Platelet-activating factor and HO-1 in mediating the protective effect of rupatadine against 5-fluorouracil-induced hepatotoxicity in rats.
Topics: Alanine Transaminase; Animals; Antioxidants; Aspartate Aminotransferases; Chemical and Drug Induced Liver Injury; Cyproheptadine; Fluorouracil; Heme Oxygenase-1; Liver; Male; Oxidative Stress; Platelet Activating Factor; Rats | 2022 |